Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to $6.5 million.

  • Guided Therapeutics' Total Liabilities rose 619.43% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year increase of 619.43%. This contributed to the annual value of $6.3 million for FY2024, which is 1446.58% up from last year.
  • Latest data reveals that Guided Therapeutics reported Total Liabilities of $6.5 million as of Q3 2025, which was up 619.43% from $6.4 million recorded in Q2 2025.
  • In the past 5 years, Guided Therapeutics' Total Liabilities registered a high of $10.3 million during Q1 2021, and its lowest value of $5.5 million during Q4 2023.
  • Its 5-year average for Total Liabilities is $6.5 million, with a median of $6.3 million in 2024.
  • Its Total Liabilities has fluctuated over the past 5 years, first tumbled by 5743.74% in 2021, then soared by 1446.58% in 2024.
  • Over the past 5 years, Guided Therapeutics' Total Liabilities (Quarter) stood at $7.5 million in 2021, then decreased by 16.51% to $6.2 million in 2022, then fell by 12.39% to $5.5 million in 2023, then increased by 14.47% to $6.3 million in 2024, then increased by 4.5% to $6.5 million in 2025.
  • Its Total Liabilities was $6.5 million in Q3 2025, compared to $6.4 million in Q2 2025 and $6.0 million in Q1 2025.